Loading
Life sciences · Journal article
Journal of Education Health and Sport · September 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Obesity is a chronic, multifactorial disease with escalating global prevalence, associated with profound metabolic, cardiovascular, and oncological comorbidities. The recent emergence of incretin-based and amylin-receptor pharmacotherapies has fundamentally transformed the landscape of obesity treatment. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA), and the investigational combination of cagrilintide - a long-acting amylin analogue - with semaglutide (CagriSema) represent two of the most clinically significant advances in weight management pharmacology. Both approaches achieve unprecedented levels of body weight reduction in clinical trials, yet differ substantially in their receptor targets, mechanisms of action, and adverse-effect profiles.